title: Controlled trial of interventions to increase testing and treatment for Helicobacter pylori and reduce medication use in patients with chronic acid-related symptoms.
abstract: BACKGROUND
  Many symptomatic patients take proton pump inhibitors or histamine-2 blockers for years and those without gastro-oesophageal reflux disease might benefit from Helicobacter pylori eradication.
  
  
  OBJECTIVE
  To increase testing and treatment of H. pylori and reduce chronic use of proton pump inhibitors and histamine-2 blockers.
  
  
  METHODS
  We conducted a three-armed controlled trial in 14 managed care practices. We included adults who used proton pump inhibitors or histamine-2 blockers for >1 year and excluded those with gastro-oesophageal reflux disease or previous endoscopy. We compared usual care (n = 312 patients from 6 practices) to low-intensity (n = 147 from 3 practices) and high-intensity (n = 122 from 5 practices) interventions. Low-intensity intervention consisted of guidelines, patient-lists, and a "toolkit"; high-intensity intervention added academic group detailing by a gastroenterologist with reinforcement by pharmacists.
  
  
  RESULTS
  Compared with usual care, the high-intensity intervention increased H. pylori test-ordering (29% versus 9% at 12 months, P = 0.02). About half (23 of 58) of patients tested positive and 22 received eradication treatments. The high-intensity intervention decreased proton pump inhibitor use by 9% per year (P = 0.028), but did not alter histamine-2 blocker use. The low intensity intervention was ineffective.
  
  
  CONCLUSIONS
  Providing guidelines, patient-lists, and toolkits was no better than usual care. Adding group detailing and pharmacist reinforcements led to improvements in H. pylori management and decreases in proton pump inhibitor use.
authors.affiliation: Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, 133 Brookline Avenue, 6th Floor, Boston, MA. 02215, USA.
authors.forename: S R
authors.initials: SR
authors.lastname: Majumdar
authors.forename: D
authors.initials: D
authors.lastname: Ross-Degnan
authors.forename: F A
authors.initials: FA
authors.lastname: Farraye
authors.forename: M
authors.initials: M
authors.lastname: Lee
authors.forename: J A
authors.initials: JA
authors.lastname: Kemp
authors.forename: R F
authors.initials: RF
authors.lastname: Lecates
authors.forename: J M
authors.initials: JM
authors.lastname: Henning
authors.forename: S R
authors.initials: SR
authors.lastname: Tunis
authors.forename: P
authors.initials: P
authors.lastname: Schrammel
authors.forename: S B
authors.initials: SB
authors.lastname: Soumerai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004415:Dyspepsia / Q000188:drug therapy*; D005260:Female; D016481:Helicobacter Infections / Q000175:diagnosis / Q000188:drug therapy*; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors
chemical_list: D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors